Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 784-791

  Macaulay, V M ^a   Middleton, M R ^a   Protheroe, A S ^a   Tolcher, A ^b   Dieras, V ^c   Sessa, C ^d   Bahleda, R ^e   Blay, J Y ^f   LoRusso, P ^g   Mery Mignard, D ^h   Soria, J C ^e  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b South Texas Accelerated Research Therapeutics (START)   (United States)

^c INSTITUT CURIE   (France)

^d SAN GIOVANNI HOSPITAL   (Switzerland)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f CENTRE LÉON BÉRARD   (France)

^g KARMANOS CANCER INSTITUTE   (United States)

^h SANOFI   (France)

Author keywords

Ave1642; Chemotherapy; Erlotinib; Monoclonal antibody; Type 1 Igf receptor

Indexed keywords

AVE 1642; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; INSULIN; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SOMATOMEDIN C RECEPTOR; STEROID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESISTANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERGLYCEMIA; LEIOMYOSARCOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA;

EID: 84874577294     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds511     Document Type: Article

References (41)

1. Chitnis MM, Yuen JS, Protheroe AS et al.. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008; 14: 6364-6370.
2. Karp DD, Paz-Ares LG, Novello S et al.. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009; 27: 2516-2522.
3. Collins IM, Beddy P, O'Byrne KJ. Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. Acta Oncol 2010; 49: 872-874.
4. Molife LR, Fong PC, Paccagnella L et al.. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010; 103: 332-339.
5. Javle MM, Varadhachary GR, Fogelman DR et al.. Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. J Clin Oncol 2011; 29 (Suppl): abstr 4026.
6. Watkins DJ, Tabernero J, Schmoll H et al.. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J Clin Oncol 2011; 29(Suppl); abstr 3501.
7. Basu B, Olmos D, de Bono JS. Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer 2011; 104: 1-3.
8. Maloney EK, McLaughlin JL, Dagdigian NE et al.. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083.
9. Sachdev D, Zhang X, Matise I et al.. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2010; 29: 251-262.
10. Spiliotaki M, Markomanolaki H, Mela M et al.. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Lung Cancer 2011; 73: 158-165.
11. Geoerger B, Brasme JF, Daudigeos-Dubus E et al.. Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma. Eur J Cancer 2011; 46: 3251-3262.
12. Descamps G, Gomez-Bougie P, Venot C et al.. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366-369.
13. Moreau P, Cavallo F, Leleu X et al.. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 2011; 25: 872-874.
14. Tolcher AW, Patnaik A, Till E et al.. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor (ST). J Clin Oncol 2008; 26(Suppl): abstr 3582.
15. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulinlike growth factors. Endocr Rev 1994; 15: 80-101.
16. Lacy MQ, Alsina M, Fonseca R et al.. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
17. Tolcher AW, Sarantopoulos J, Patnaik A et al.. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
18. Kurzrock R, Patnaik A, Aisner J et al.. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 2458-2465.
19. Cerny T, Kaplan S, Pavlidis N et al.. Docetaxel (Taxotere) is active in non-smallcell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994; 70: 384-387.
20. Miller VA, Rigas JR, Francis PA et al.. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995; 75: 968-972.
21. Boeck S, Vehling-Kaiser U, Waldschmidt D et al.. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs 2010; 21: 94-100.
22. Okusaka T, Furuse J, Funakoshi A et al.. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 2011; 102: 425-431.
23. Sledge GW, Neuberg D, Bernardo P et al.. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21: 588-592.
24. Juergens H, Daw NC, Geoerger B et al.. Preliminary efficacy of the anti-insulinlike growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29: 4534-4540.
25. Sachdev D, Singh R, Fujita-Yamaguchi Y et al.. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006; 66: 2391-2402.
26. Belfiore A, Frasca F, Pandini G et al.. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30: 586-623.
27. Haluska P, Shaw HM, Batzel GN et al.. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
28. Atzori F, Tabernero J, Cervantes A et al.. A phase I, pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-IGF-1R monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 6304-6312.
29. Aamdal S, Wolff I, Kaplan S et al.. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994; 30A: 1061-1064.
30. Ferraresi V, Ciccarese M, Cercato MC et al.. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol 2008; 63: 149-155.
31. Pappo AS, Patel SR, Crowley J et al.. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 2011; 29: 4541-4547.
32. Warshamana-Greene GS, Litz J, Buchdunger E et al.. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005; 11: 1563-1571.
33. Haluska P, Carboni JM, Loegering DA et al.. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66: 362-371.
34. Flanigan SA, Pitts TM, Eckhardt SG et al.. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res 2010; 16: 5436-5446.
35. Turney BW, Kerr M, Chitnis MM et al.. Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol 2012; 103: 402-409.
36. Zeng X, Zhang H, Oh A et al.. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat 2011; 133: 117-126.
37. Gualberto A, Hixon ML, Karp DD et al.. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2010; 104: 68-74.
38. Habben K, Delmar P, Brownstein CM et al.. Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy. J Clin Oncol 2011; 29: 7584.
39. Ramalingam SS, Spigel DR, Steins M et al.. Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29 (Suppl 20): 7527.
40. Goto Y, Sekine I, Tanioka M et al.. Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. Invest New Drugs 2011; 30: 1548-1556.
41. Bid HK, Zhan J, Phelps DA et al.. Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2. Mol Cancer Ther 2011; 11: 649-659.